“Dedication, purpose, impact, world-leading science”—those are some of the reasons people want to work at this biotech firm, which aims to combat a range of diseases and has four FDA-approved drugs. In a “world driven by the dollar,” says one employee, it’s “refreshing” to be at a company where the “bottom line is with patients.”
Learn more in the Great Place to Work review here.
News about Regeneron Pharmaceuticals
Amgen says Repatha sold $271 million in the first half of 2018, despite earlier predictions of multi-billion-dollar sales.
Scientists are ready to move an experimental treatment into phase 1 trials.
“We should only be working on two things, health and the freaking environment.”
But Dupixent's high cost could be a problem.